About
DCxBio develops next-generation precision multi-modal antibody drug conjugates that target cancer by identifying lesion-specific intracellular and cell-surface targets using an integrated CRISPR, bioinformatics, and machine learning platform.
Explore DCxBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.